USTRx Act
Official title: To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes.
What Do You Think?
How would you vote?
Vote to see the result.
What Happened in Congress?
Not yet voted on the floor.
Where the Bill Stands
- Introduced, done
- Committee, current stage
- Floor Vote, not yet
- Outcome, not yet
What This Bill Does
This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.
The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.
The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.
Sponsors
Related Documents
Timeline
- Library of CongressIntroduced in House
- House floor actionsReferred to the House Committee on Ways and Means.
- Introduced
- Committee
Comments
Comments with insults, hate speech or personal information are removed.